AngioDynamics Azione

AngioDynamics Debito/EBITDA

Il Rapporto Debiti Totali / EBITDA di AngioDynamics (ANGO) al 14 ago 2026 è 1,38. L'anno precedente, Rapporto Debiti Totali / EBITDA era -0,21 — una variazione del -760,18% (superiore).

Debito/EBITDA

1,38

YoY

-760,18%

Ultimo aggiornamento:

Rapporto Debiti Totali / EBITDA di AngioDynamics ammonta a 2026 1,38 . Rapporto Debiti Totali / EBITDA di AngioDynamics ammontava a 2025 -0,21 . Diminuisce del -760,18% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

AngioDynamics Analisi delle Azioni

Cosa fa AngioDynamics? AngioDynamics Inc is a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company was founded in 1988 and is headquartered in Latham, New York. Over the years, AngioDynamics has evolved into a conglomerate through several acquisitions and partnerships, specializing in various areas. The key divisions include Vascular Access Solutions, Oncology Solutions, and Peripheral Vascular Solutions. AngioDynamics focuses on developing and manufacturing innovative technologies that improve medical care and promote patient health. The company develops and distributes a wide range of medical devices and procedures to treat diseases such as cancer, venous diseases, and thrombosis. In the Vascular Access Solutions division, AngioDynamics offers a wide range of devices for establishing vascular access, which are necessary for the treatment of serious illnesses. This includes port systems and catheters that facilitate access to the body's vascular system. AngioDynamics' Oncology Solutions provide targeted cancer treatment options, including ultrasound-controlled radiofrequency ablation systems and fusion biopsy systems. The development of innovative diagnostic and treatment options is a focus of AngioDynamics. A majority of AngioDynamics' products are in the Peripheral Vascular Solutions division. Here, the company develops devices and procedures for the treatment of peripheral vascular diseases such as varicose veins or chronic venous insufficiency. This includes procedures like laser and radiofrequency treatments that can be performed minimally invasively. AngioDynamics has gained an excellent reputation in the medical industry due to its high-quality products, innovative technologies, and close collaboration with medical professionals. The company places great emphasis on providing optimal care to every patient and therefore serves hospitals, clinics, and medical practices worldwide. Over the years, AngioDynamics has become a leading provider of medical devices and solutions for the treatment of vascular diseases and cancer. The company has built a broad customer base worldwide and has become an important player in the medical industry due to the quality and innovation of its products. AngioDynamics è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su AngioDynamics azioni

Rapporto Debiti Totali / EBITDA di AngioDynamics è 1,38 nel 2026.

Il Rapporto Debiti Totali / EBITDA di AngioDynamics è passato da -0,21 a 1,38, con una variazione del -760,18 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del AngioDynamics di Rapporto Debiti Totali / EBITDA dal 2006, con valori annuali, grafici e analisi dettagliate.

Debiti/EBITDA misura il debito totale rispetto agli utili prima di interessi, imposte, ammortamenti e accantonamenti. Indica gli anni necessari per ripagare tutto il debito dall'EBITDA.

Un 'buono' varia a seconda del settore e della fase di sviluppo dell'azienda. Su Eulerpool puoi confrontare AngioDynamics di Rapporto Debiti Totali / EBITDA con i competitor del settore e la media industriale per valutare se è attraente.

Access this data via the Eulerpool API

Leva finanziaria — AngioDynamics

Tutte le Metriche Finanziarie — AngioDynamics